Ratha Mahendran

Mahendran Ratha

  • Senior Research Fellow, Department of Surgery
Administrative Appointment(s)
  • Member, Institutional Biosafety Committee, National University of Singapore
  • Member, MD4 & MD11 Central Research Facilities Safety Committee, NUS Yong Loo Lin School of Medicine
  • Member, NUHS Internal Grants Review Committee
Academic Qualifications
  • PhD, University of Texas at Dallas, USA
  • BSc (Honours), National University of Singapore, Singapore
Research Interest(s)
  • Bladder Cancer
  • Immunotherapy
  • SNPs
  • BCG
  • Animal Models
Recent Publications
  • 1. Yip LY, Aw CC, Lee SH, Hong YS, Ku HC, Xu WH, Chan JMX, Cheong EJY, Chng KR, Ng AHQ et al. 2018 Jan. The liver-gut microbiota axis modulates hepatotoxicity of tacrine in the rat. Hepatology. 67(1):282-295. doi: 10.1002/hep.29327.
  • 2. Mahendran R. 2017 Feb. Bacillus Calmette-Guerin immunotherapy-increasing dose as a means of improving therapy? Translational Cancer Research. 6:S168-S173. doi: 10.21037/tcr.2017.01.25.
  • 3. Tham SM, Esuvaranathan K, Mahendran R. 2017 Jan. A Murine Orthotopic Bladder Tumor Model and Tumor Detection System. Jove-Journal of Visualized Experiments. e55078. doi: 10.3791/55078.
  • 4. Ang WX, Zhao Y, Kwang T, Wu C, Chen C, Toh HC, Mahendran R, Esuvaranathan K, Wang S. 2016 Jun. Local Immune Stimulation by Intravesical Instillation of Baculovirus to Enable Bladder Cancer Therapy. Scientific Reports. 6:27455. doi: 10.1038/srep27455.
  • 5. Lu S, Xu L, Kang ET, Mahendran R, Chiong E, Neoh KG. 2016 Mar. Co-delivery of peptide-modified cisplatin and doxorubicin via mucoadhesive nanocapsules for potential synergistic intravesical chemotherapy of non-muscle-invasive bladder cancer. European Journal of Pharmaceutical Sciences. 84:103-115. doi: 10.1016/j.ejps.2016.01.013.